Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors Apr 24, 2018 Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 Apr 15, 2018 Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors Apr 11, 2018 Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb Apr 03, 2018 Nektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston Mar 07, 2018 Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Mar 01, 2018 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets Feb 21, 2018 Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214 Feb 14, 2018 Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 03, 2018 Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City Nov 27, 2017 Pagination First page « first Previous page ‹ previous … Page 14 Page 15 Page 16 Page 17 Current page 18 Page 19 Page 20 Page 21 Page 22 … Next page next › Last page last »